New analogues of AHMA as potential antitumor agents: synthesis and biological activity.
暂无分享,去创建一个
Shu-Yun Cheng | Jang-Yang Chang | Li-Tzong Chen | T. Chou | Jang-Yang Chang | Ting-Chao Chou | Wen-Yu Pan | Ching-Huang Chen | Tsann-Long Su | Ching-Huang Chen | T. Su | Huajin Dong | Yi-Wen Lin | Chyun-Feng Lin | Valeriy Bacherikov | Tsong-Jen Tasi | Kuo-Tung Chen | Shu-Yun Cheng | W. Pan | Yi-Wen Lin | Huajin Dong | K. Chen | Li‐Tzong Chen | V. Bacherikov | C. Lin | Tsong-Jen Tasi
[1] T. Chou,et al. 9-substituted acridine derivatives with long half-life and potent antitumor activity: synthesis and structure-activity relationships. , 1995, Journal of medicinal chemistry.
[2] L. Malspeis,et al. Metabolism of 4'-(9-acridinylamino)methanesulfon-m-anisidide by rat liver microsomes. , 1984, Cancer research.
[3] L. Liu,et al. DNA damage by antitumor acridines mediated by mammalian DNA topoisomerase II. , 1986, Cancer research.
[4] G. Atwell,et al. Potential antitumor agents. 14. Acridylmethanesulfonanilides. , 1974, Journal of medicinal chemistry.
[5] T C Chou,et al. Synthesis and structure-activity relationships of potential anticancer agents: alkylcarbamates of 3-(9-acridinylamino)-5-hydroxymethylaniline. , 1999, Journal of medicinal chemistry.
[6] A. Leo,et al. Potential antitumor agents. 36. Quantitative relationships between experimental antitumor activity, toxicity, and structure for the general class of 9-anilinoacridine antitumor agents. , 1982, Journal of medicinal chemistry.
[7] G. Atwell,et al. Potential antitumor agents. 12. 9-Anilinoacridines. , 1972, Journal of medicinal chemistry.
[8] W. Denny,et al. Potential antitumor agents. 34. Quantitative relationships between DNA binding and molecular structure for 9-anilinoacridines substituted in the anilino ring. , 1981, Journal of medicinal chemistry.
[9] L. Liu,et al. Mechanism of antitumor drug action: poisoning of mammalian DNA topoisomerase II on DNA by 4'-(9-acridinylamino)-methanesulfon-m-anisidide. , 1984, Proceedings of the National Academy of Sciences of the United States of America.
[10] T. Chou,et al. Synergism and antagonism in chemotherapy , 1991 .
[11] B. Palmer,et al. Differences in the metabolism of the antitumour agents amsacrine and its derivative CI-921 in rat and mouse. , 1992, Xenobiotica; the fate of foreign compounds in biological systems.
[12] A. Montecucco,et al. DNA unwinding and inhibition of T4 DNA ligase by anthracyclines. , 1988, Nucleic acids research.
[13] Yves Pommier,et al. DNA interaction and topoisomerase II inhibition by the antitumor agent 3'-(9-acridinylamino)-5'-hydroxymethylaniline and derivatives , 1996 .
[14] H. Nakano,et al. Induction of mammalian DNA topoisomerase I and II mediated DNA cleavage by saintopin, a new antitumor agent from fungus. , 1991, Biochemistry.
[15] W. Denny,et al. Potential antitumor agents. 35. Quantitative relationships between antitumor (L1210) potency and DNA binding for 4'-(9-acridinylamino)methanesulfon-m-anisidide analogues. , 1981, Journal of medicinal chemistry.
[16] W. Denny,et al. Synthesis, antitumor activity, and DNA binding properties of a new derivative of amsacrine, N-5-dimethyl-9-[(2-methoxy-4-methylsulfonylamino) phenylamino]-4-acridinecarboxamide. , 1984, Cancer research.
[17] W. Denny,et al. Potential antitumor agents. 46. Structure-activity relationships for acridine monosubstituted derivatives of the antitumor agent N-[2-(dimethylamino)ethyl]-9-aminoacridine-4-carboxamide. , 1986, Journal of medicinal chemistry.
[18] C. Hansch,et al. Quantitative structure-activity relationships (QSAR) for 9-anilinoacridines: a comparative analysis. , 1998, Chemico-biological interactions.
[19] H. M. Sobell,et al. Visualization of drug-nucleic acid interactions at atomic resolution. IV. Structure of an aminoacridine--dinucleoside monophosphate crystalline complex, 9-aminoacridine--5-iodocytidylyl (3'--5') guanosine. , 1979, Journal of molecular biology.
[20] D. Scudiero,et al. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. , 1988, Cancer research.
[21] L. Liu,et al. Cleavage of DNA by mammalian DNA topoisomerase II. , 1983, The Journal of biological chemistry.
[22] K. Kohn,et al. Topoisomerase II-mediated DNA damage produced by 4'-(9-acridinylamino)methanesulfon-m-anisidide and related acridines in L1210 cells and isolated nuclei: relation to cytotoxicity. , 1988, Cancer research.
[23] L. Liu,et al. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. , 1988, Cancer research.
[24] T. Chou,et al. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.
[25] F. Della Seta,et al. Structure of RNA polymerase II promoters. Conformational alterations and template properties of circularized Saccharomyces cerevisiae GAL1‐GAL10 divergent promoters. , 1986, The EMBO journal.
[26] Y. Pommier,et al. Correlations between intercalator-induced DNA strand breaks and sister chromatid exchanges, mutations, and cytotoxicity in Chinese hamster cells. , 1985, Cancer research.
[27] Jang-Yang Chang,et al. Antitumor AHMA linked to DNA minor groove binding agents: synthesis and biological evaluation. , 2002, Journal of medicinal chemistry.
[28] W. Denny,et al. Potential antitumor agents. 27. Quantitative structure--antileukemic (L1210) activity relationships for the omega-[4-(9-acridinylamino)phenyl]alkanoic acids. , 1978, Journal of medicinal chemistry.